BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionBessemer Group Inc
Latest Disclosed Ownership2,086 shares
Latest Disclosed Value $ 155
Bessemer Group Inc reports 1.14% decrease in ownership of BBIO / BridgeBio Pharma, Inc.

On May 6, 2026 - Bessemer Group Inc filed a 13F-HR form disclosing ownership of 2,086 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $154,906 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 2,110 shares of BridgeBio Pharma, Inc.. The current value of the position is $136,591 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F BRIDGEBIO PHARMA SC 10806X102 2,086 -24 -1.14 0 0.0002
2026-02-05 2025-12-31 13F BRIDGEBIO PHARMA SC 10806X102 2,110 0 0.00 0 0.0002
2025-11-05 2025-09-30 13F BRIDGEBIO PHARMA SC 10806X102 2,110 1,772 524.26 0 0.0002
2025-08-01 2025-06-30 13F BRIDGEBIO PHARMA SC 10806X102 338 170 101.19 0 0.0000
2025-04-23 2025-03-31 13F BRIDGEBIO PHARMA SC 10806X102 168 28 20.00 0 0.0000
2025-02-13 2024-12-31 13F BRIDGEBIO PHARMA SC 10806X102 140 0 0.00 0 0.0000
2024-11-12 2024-09-30 13F BRIDGEBIO PHARMA SC 10806X102 140 140 0 0.0000
2022-08-10 2022-06-30 13F BRIDGEBIO PHARMA SC 10806X102 0 -77 -100.00 0 -100.00
2022-05-12 2022-03-31 13F BRIDGEBIO PHARMA SC 10806X102 77 0 0.00 1 0.00 0.0000
2022-01-27 2021-12-31 13F BRIDGEBIO PHARMA SC 10806X102 77 -1,656 -95.56 1 -98.77 0.0000
2021-11-12 2021-09-30 13F BRIDGEBIO PHARMA SC 10806X102 1,733 0 0.00 81 -23.58 0.0002
2021-08-06 2021-06-30 13F BRIDGEBIO PHARMA SC 10806X102 1,733 0 0.00 106 -0.93 0.0002
2021-05-13 2021-03-31 13F BRIDGEBIO PHARMA SC 10806X102 1,733 1,733 107 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.